Search results
Earnings call: Jazz Pharmaceuticals sustains growth with key drivers By Investing.com
Investing.com· 16 hours agoJazz Pharmaceuticals PLC (NASDAQ:JAZZ) has reported robust first-quarter 2024 results, showcasing...
She had Parkinson's and didn't want to live. Then she got this surgery.
USA TODAY via Yahoo News· 3 days ago"I didn't want to live with the symptoms I was having," the 64-year-old says, grieving her life...
Baird starts Praxis shares coverage with outperform, cites promising drug By Investing.com
Investing.com· 2 days agoInc. (NASDAQ: PRAX), assigning an Outperform rating to the company's shares with a price target of...
Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 2 days agoThe firm views Praxis' ulixacaltamide as "a promising agent" for the treatment of essential tremor...
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Zacks via Yahoo Finance· 6 days agoSage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoSage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024 Sage...
'They're not alone': Longview Parkinson's support group offers education, connection
The Longview News-Journal· 3 days agoDetecting the signs and symptoms of Parkinson’s disease early is the best way for someone who has it...
Short Interest in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Expands By 77.1%
ETF DAILY NEWS· 4 days agoPraxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest ...
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright
ETF DAILY NEWS· 4 days agoHC Wainwright reissued their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have ...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN...
The Herald Journal· 2 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug ...